Dusa/Berlex Levulan Actinic Keratoses Recurrence Phase IV Study Planned
Dusa has committed to a Phase IV study of the actinic keratoses treatment Levulan Kerastick to assess the long-term recurrence rate of treated lesions over a 12-month follow-up period.
You may also be interested in...
Berlex will begin hiring reps in December for its new U.S. dermatology sales force, which will promote Dusa's Levulan for actinic keratoses.
Dusa Levulan Kerastick labeling which includes a 75% partial lesion clearance response for the actinic keratoses treatment could benefit clinicians and patients, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee decided Nov. 5.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011